Original Publications in Peer-Reviewed Journals

1. Ho CY, Otterud B, Legare RD, Varvil T, Saxena R, DeHart DB, Kohler SE, Aster JC, Dowton SB, Li FP, Leppert M, Gilliland DG. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood. 1996 June 15; 87(12): 5218-5224.
   
   
2. Legare RD, Ho CY, Otterud B, et al. A familial platelet disorder with propensity to develop acute myeloid leukemia is linked to human chromosome 21q22.1-q22.2. Cytogenet Cell Genet 79 (102): 51-52 1997.
   
   
3. Legare RD, Lu D, Gallagher M, Ho CY, Barke, G, Shimizu K, Ohki M, Lenny N, Hiebert S. Gilliland, DG. CBFA2, Frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome. Leukemia. 1997 Dec; 11(12):2111-2119.
   
   
4. Legare RD, Gribben JG, Maragh M, Hermanowski-Vosatka A, Roach S, Tantravahi R, Nadler LM, Gilliland DG. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol. 1997 Sept, 56 (1):45-51.
   .
5. Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS, Nadler LM, Gribben JG, Gilliland DG. Predictive value of clonality assays in patients with non-hodgkin's lymphoma undergoing autologous bone marrow transplant: A single institution study. Blood 1998 June; 91(12):4496-4503.
   
   
6. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nature Genetics, 1999 October; 23(2):166-175.
   
   
7. Cools J, DeAngelo D, Gotlib J, Stover EH, Legare RD, Malone J, Kutok J, Clark J, Galinsky I, Griffin J, Cross N, Tefferi A, Alam R, Cortes J, Kantarjian H, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Marynen P, Coutre S, Stone R, Gilliland DG. A novel tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndromes. N Engl J Med 2003 March 27;348:1201-1214.
   
   
8. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams R, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland G. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR A-induced myeloproliferative disease. Cancer Cell 2003 May;3(5): 459-469.
   
   
9. Pinto BM., Trunzo, JJ., Rabin C., Cady B., Fenton MA., Hernan A., Legare RD, Sikov W., Recruitment strategies for a home-based physical activity intervention for breast cancer patients. Journal of Clinical Pathology in Medical Settings 2004 September; 11(3): 171-178.
   
   
10. Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, DiSilvestro P, Gordinier ME, Moore R, Tejada-Berges T, Pires L, Legare RD, Granai CO. Two for good measure: Six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecol Oncol. 2006 February; 100(2):417-421.
    
    
11. Dizon DS, Schwartz J, Rjoan A, Miller J, Pires L, DiSilvestro P, Gordinier ME, Moore R, Granai CO, Legare RD. Cross-Sensitivity Between Paclitaxel and Docetaxel in a Women's Cancers' Program. Gynecol Oncol, 2006 January;100(1):149-151.

Other Non-Peer-Reviewed Publications

1. Legare RD, Gilliland DG. Myelodysplastic syndrome. Curr Opin in Hematol. 1995 July; 2(4):283-292.
   
   
2. Legare RD. Screening and management of hereditary breast cancer. Medicine and Health/RI. 1999 May; 82(5): 172-175.
   
   
3. Atlas I, Granai CO, Gajewski W, Steinhoff MM, Steller M, Falkenberry S, Legare R, Szvalb S, Prober A, Zafrir H, Farbstein J. Videoconferencing for gynecological cancer care: an internal tomour board. J Telemed Telecare. 2000; 6(4):242-4.
   
   
4. Falkenberry SS, Chung M, Legare R, Strenger R, Wallace D, Phipps D, Morry S, Marchant DJ, Cady B. The Breast Health Center at Women & Infants Hospital: origin, philosophy, and features. Surgical Oncol Clin N Am. 2000 Apr;9(2):199-216.
   
   
5. Scalia JL, Legare RD, Identification and management of hereditary breast and ovarian cancer. Medicine and Health/RI 2003 February; 86(2):48-51.

Books and Book Chapters

1. Gajewski WH, Legare RD. Ovarian Cancer. Surgical Oncology Clinics of North America, Cancers Unique to Women, WB Saunders, Publisher;7(2):317-333, Apr. 1998.
   
   
2. Granai, CO, Gajewski, WH, Legare R. Section on Gynecologic Cancers: Handbook of Cancer Chemotherapy. Fifth Edition. Little Brown and Company, June, 1999
   
   
3. Legare RD. Chemotherapeutic Agents. Medical Care of the Pregnant Patient, 2000, Chapter 11: 619-26.
   
   
4. Legare RD, Strenger R. Adjuvant Therapy in Breast Cancer. Obstet Gynecol Clin North Am.,2002 March;29(1):201-8.
   
   
5. Falkenberry SS, Legare RD. Risk Factors for Breast Cancer. Obstet Gynecol Clin North Am, 2002 March;29(1):159-72.
   
   
6. Granai CO, Gajewski WH, Legare RD. Gynecologic Cancer in the Handbook of Cancer Chemotherapy Sixth Edition, Lippincott Williams & Wilkins; 294-326, Mar. 2003.
   
   
7. Wilbur JS, Rojan AA, Legare RD: The Genetics of Breast and Gynecological Cancers. In Textbook of General Gynecology: Requisites in Obstetrics and Gynecology, (eds.) Sokol & Sokol, In Press; June, 2006.

Abstracts

1. Legare RD, Gribben JG, Busque L, et al. Clonal Hematopoiesis is predictive of secondary myelodysplasia in autologous bone-marrow transplant (ABMT) for non-Hodgkins-Lymphoma (NHL) Blood, 84 (10): A495-A495 Suppl. 1 Nov 15 1994.
   
   
2. Legare RD, Ho CY, Otterud B, et al. A familial platelet disorder with propensity to develop acute Myeloid Leukemia is linked to human chromosome 21q22.1-q22.2. Am J Hum Genet 57 (4):109-109 Suppl. S Oct 1995.
   
   
3. Legare RD, Gribben JG, Nadler LM, et al. Predicition of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Blood 86 (10): 1586-1586 Suppl. 1 Nov 15 1995.
   
   
4. Legare RD, Ho CY, Otterud B, et al. A familial platelet disorder with propensity to develop acute myeloid leukemia is linked to human chromosome 21q22.1-22.2. Blood, 86 (10): 3056-3056 Suppl. 1 Nov 15 1995.
   
   
5. MachPascual S, Lu D, Gribben JG, Legare RD, et al. Prevalence of clonal hematopoiesis in 60 patients with non-Hodgkin's lymphoma (NHL) at the time of autologous bone – marrow transplantation (ABMT). Blood 88 (10): 2710-2710 Part 1 Suppl. 1 Nov 15 1996.
   
   
6. MachPascual S, Legare RD, Lu D, et al. Predictive value of clonality analysis in patients with non-Hodgkin's lymphoma (NHL) undergoing autologous bone marrow transplant (ABMT): A single institution study. Blood 90 (10): 2626-2626 Part 1 Suppl. 1 Nov 15 1997.
   
   
7. Kim P, Akerley W., Safran H, Pryzgoda J, Strenger R, Sikov W, Rege V, Kennedy T, Legare RD. Brown University Oncology Group (BrUOG), Providence, RI. Vinorelbine and estramustine for previously treated, advanced breast cancer (ABC). Proceedings of ASCO,1999; 18: pg. 133a.
   
   
8. Sikov W, Akerley W, Strenger R, Legare RD, et al. Weekly high-dose paclitaxel in locally advanced and metastatic breast cancer: A BrUOG study, Providence, RI. Semin Oncol 26 (6): 6-6 Suppl. 18 Dec 1999.
   
   
9. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 (AML1) causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia (FPD/AML). Blood 94 (10): 3007 Part 1 Suppl. 1 Nov 15 1999.
   
   
10. Legare RD, McCarthy M, McGowan K, Schepps B, Graziano, KE, Henseler SM, Miller MA, Fulton J, Mark HFL. The state of breast cancer in RI. The Genetic Resource 1999, 12 (No. 1 & 2).
    
    
11. Wilbur JS, Cady B, Legare RD. Surgical procedures resulting from BRCA gene analysis results. San Antonio Breast Cancer Symposium, 2003; 333: pg.42.
    
    
12. Wilbur JS, McDonnel MK, Cady B, Legare RD. The cancer risk assessment and prevention program database enhances practical management and promotes clinical research of patient data within a cancer genetics program. American Society of Human Genetics, 2003; 428: pg.123.
    
    
13. Wiggins D, Gass J, Granai C, Legare R, Dizon D. Pre-operative concordance of radiology and pathologic findings in T1 breast cancers. 24th Annual New England Association of Gynecologic Oncologists, June 12, 2004.
    
    
14. Legare RD, Wilbur JS. DCIS as a Component of the Breast Ovarian Cancer Syndrome. ASCO - San Antonio Breast Cancer Symposium; Abstract 4021, 2005.
    
    
15. Legare RD, Brown EK, Wilbur JS. The relationship between BRCA1 mutations and uterine serous papillary carcinoma in Ashkenazi Jewish women. American Society of Human Genetics; Abstract 20747, 2005.
    
    
16. Wilbur JS, Sousa TR, Legare RD. MRI fails to detect invasive breast cancer in a BRCA2 positive patient. American Society of Human Genetics; Abstract 30411, 2005.
    
    
17. Fenton MA, Ries LM, STrenger R, Dizon DS, Legare RD, Joseph PJ, Theall KP, Graves TA, Gass JS, Sikov WM. Frequent pathologic complete responses seen with neoadjuvant q4week carboplatin and weekly paclitaxel weekly trastuzumab in resectable and locally advanced breast cancer. San Antonio Breast Cancer Symposium; Abstract 5054, 2005; 94: pg.224.
    
    
18. Schwartz JR, Bradley A, Bandera C, Brard L, DiSilvestro P, Legare R, Moore R, Tejada-Berges T, Granai CO, Dizon DS,. Does the platinum-free interval predict the incidence or severity of hypersensitivity to carboplatin? Proceedings of ASCO, 2006; 24: pg.276s.
    
    
19. Wilbur JS, Kent JL, Gass JS Brown EK, Legare RD, Respecting patient confidentiality and professional disclosure while avoiding potential patient harm. American Society of Human Genetics; Abstract 973/C, 2006.
    
    
20. Kent JL, Wilbur JS, Legare RD, Characterization of no-show patients in a cancer genetics clinic. National Society of Genetic Counselors; [Abstract 249], 2006.
    
    
21. Legare RD, Kent JL, Wilbur, JS, Gass, JS, Wiggins DL, Tejada-Berges T, Dizon DS, Phenotype of BRCA-associated breast malignancy in a high risk clinic. San Antonio Breast Cancer Symposium; Abstract 4027, 2006.
    
    
22. Stuckey A, Legare R, Wilbur J, Kent J, Dizon D, Tejada-Berges T., Gass J, Clinical Characteristics and Choices Regarding Prophylactic Surgery in BRCA Mutation Carriers. American Society of Breast Surgeons; Abstract Submitted, 2007.
    
    
23. Wilbur JS, Brown EK, Kent JL, Tejada-Berges T, Moore RG, Legare RD, Analysis of ovarian cancer patient referrals to a high risk cancer genetics clinic. Society of Gynecological Oncologists; Abstract Submitted, 2007.
    
    
24. Rojan A, McDonough K, Sung J, Steinhoff M, Tsiapali E, Strenger R, Sikov W, Wiggins D, Tejada-Berges T, Legare R, Quddus M, Lack of survival differences seen in HER-2/neu positive breast cancers stratified by hormone receptor status. American Society of Breast Surgeons; Abstract 293211, 2007.
    
    
25. Legare, RD., Wilbur, JS., Kent, J. The Importance of Continued Surveillance of High Risk Cancer Families as Illustrated in a Family with Gardner's Syndrome. American Society of Clinical Oncologists; Abstract Submitted, 2007.